» Articles » PMID: 33028316

Implementing a Clinical Cutting-edge and Decision-making Activity: an Ethnographic Teamwork Approach to a Molecular Tumorboard

Overview
Publisher Biomed Central
Specialty Health Services
Date 2020 Oct 8
PMID 33028316
Authors
Affiliations
Soon will be listed here.
Abstract

Background: New technology implementation in healthcare must address important challenges such as interdisciplinary approaches. In oncology, molecular tumorboard (MTB) settings require biomedical researchers and clinical practitioners to collaborate and work together. While acknowledging that MTBs have been primarily investigated from a clinical rather than an organizational perspective, this article analyzes team processes and dynamics in a newly implemented MTB.

Methods: A systemic case study of a newly implemented MTB in a Swiss teaching hospital was conducted between July 2017 and February 2018, with in situ work observations, six exploratory interviews and six semi-structured interviews.

Results: An MTB workflow is progressively stabilized in four steps: 1) patient case submissions, 2) molecular analyses and results validation, 3) co-elaboration of therapeutic proposals, and 4) reporting during formal MTB sessions. The elaboration of a therapeutic proposal requires a framework for discussion that departs from the formality of institutional relationships, which was gradually incepted in this MTB.

Conclusions: Firstly, our research showed that an MTB organizational process requires the five teaming components that characterizes a learning organization. It showed that at the organizational level, procedures can be stabilized without limiting practice flexibility. Secondly, this research highlighted the importance of non-clinical outcomes from an MTB, e.g. an important support network for the oncologist community.

References
1.
Good B, Ainscough B, McMichael J, Su A, Griffith O . Organizing knowledge to enable personalization of medicine in cancer. Genome Biol. 2014; 15(8):438. PMC: 4281950. DOI: 10.1186/s13059-014-0438-7. View

2.
Bardia A, Iafrate J, Sundaresan T, Younger J, Nardi V . Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital. Oncologist. 2016; 21(9):1035-40. PMC: 5016066. DOI: 10.1634/theoncologist.2016-0240. View

3.
Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N . A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018; 29(9):1895-1902. PMC: 6158764. DOI: 10.1093/annonc/mdy263. View

4.
Chin L, Andersen J, Futreal P . Cancer genomics: from discovery science to personalized medicine. Nat Med. 2011; 17(3):297-303. DOI: 10.1038/nm.2323. View

5.
McGowan M, Ponsaran R, Silverman P, Harris L, Marshall P . "A rising tide lifts all boats": establishing a multidisciplinary genomic tumor board for breast cancer patients with advanced disease. BMC Med Genomics. 2016; 9(1):71. PMC: 5117517. DOI: 10.1186/s12920-016-0234-1. View